It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lynch Syndrome (LS) is an autosomal dominant disease conferring a high risk of colorectal cancer due to germline heterozygous mutations in a DNA mismatch repair (MMR) gene. Although cancers in LS patients show elevated somatic mutation burdens, information on mutation rates in normal tissues and understanding of the trajectory from normal to cancer cell is limited. Here we whole genome sequence 152 crypts from normal and neoplastic epithelial tissues from 10 LS patients. In normal tissues the repertoire of mutational processes and mutation rates is similar to that found in wild type individuals. A morphologically normal colonic crypt with an increased mutation burden and MMR deficiency-associated mutational signatures is identified, which may represent a very early stage of LS pathogenesis. Phylogenetic trees of tumour crypts indicate that the most recent ancestor cell of each tumour is already MMR deficient and has experienced multiple cycles of clonal evolution. This study demonstrates the genomic stability of epithelial cells with heterozygous germline MMR gene mutations and highlights important differences in the pathogenesis of LS from other colorectal cancer predisposition syndromes.
It is unclear whether somatic mutation rates are elevated in Lynch Syndrome (LS), which is the most common cause of hereditary colorectal cancer. Here, the authors use whole-genome sequencing and organoid cultures to show that normal tissues in LS patients are genomically stable, while ancestor cells of neoplastic tissues undergo multiple cycles of clonal evolution.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 The University of Hong Kong, Queen Mary Hospital, Hereditary Gastrointestinal Cancer Genetic Diagnosis Laboratory, Department of Pathology, School of Clinical Medicine, Pokfulam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757)
2 Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); University of Cambridge, Department of Paediatrics, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
3 Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
4 University of Oxford, Headington, Nuffield Department of Surgical Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 The University of Hong Kong, Queen Mary Hospital, Hereditary Gastrointestinal Cancer Genetic Diagnosis Laboratory, Department of Pathology, School of Clinical Medicine, Pokfulam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, Centre for PanorOmic Sciences, Pokfulam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757)